LEGN earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -17.30. Updated 2026-07-23.
Legend Biotech (LEGN) Research Hub
Legend Biotech (LEGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 20.39 USD (+5.81%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -17.30, market cap 4.30B. This hub links to the full technical, earnings and options research available for LEGN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 20.39 USD (+5.81%) |
| 52-week range | 16.86 USD – 36.18 USD |
| Trend regime | Range |
| 14-day RSI | 60.8 (Bullish) |
| Trailing P/E | -17.30 |
| Market cap | 4.30B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for LEGN
Covered Call on LEGN: how it works, illustrative setup around the real 20.39 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LEGN: how it works, illustrative setup around the real 20.39 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LEGN: how it works, illustrative setup around the real 20.39 USD price, max profit/loss, breakeven and when to use it. Educational.
LEGN technical analysis: range, last 20.39 USD, RSI 60.8, 52w range 16.86 USD–36.18 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is LEGN in?
Legend Biotech (LEGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LEGN in an uptrend or downtrend?
As of 2026-10-26, LEGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LEGN's trailing P/E ratio?
LEGN's trailing P/E is -17.30, with a market cap of 4.30B. See the earnings research page for full valuation detail.
When does LEGN next report earnings?
LEGN is next scheduled to report earnings on 2026-08-10.